When AI designs a drug, who gets the credit?

The Story At A Glance

• • Insilico Medicine used its Pharma.AI platform to identify the TNIK target and design the drug rentosertib.


• • Legal and scientific credit remains with the human researchers and the corporation rather than the software.


• • AI serves as a high speed accelerator for identifying molecules and optimizing drug candidates.

Context
Biotech companies are increasingly using generative AI to bypass traditional, slow discovery methods. This shift moves drug development from manual trial and error to rapid, model driven optimization.

Christian Perspective
Man is created in the image of God and possesses the unique intellect to command tools like AI. While machines can process data, they lack the divine spark and moral agency required for true creation. We must ensure that technology remains a servant to human stewardship rather than an idol that replaces human responsibility.

Implications
The acceleration of drug discovery can preserve life, which aligns with the biblical mandate to care for the sick. However, the concentration of this power in massive biotech corporations poses a risk to individual liberty and bodily autonomy. We must guard against a future where AI driven medicine is used to enforce mandates or control the population.

Broader Trends
This technological shift mirrors the broader trend of replacing human agency with algorithmic systems. As globalist entities seek to automate decision making, the distinction between human wisdom and machine output becomes blurred. This centralization of scientific power often benefits elite interests over the common good of the nation.

Takeaway
Prioritize American innovation and ensure that the benefits of these breakthroughs serve the domestic population first. We must maintain strict human oversight to prevent the subversion of natural order by autonomous systems. Use these tools to strengthen the nation and protect the sanctity of life without surrendering human sovereignty to the machine.